SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-24-002050
Filing Date
2024-04-02
Accepted
2024-04-02 07:30:12
Documents
15
Period of Report
2024-04-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT phio_8k.htm   iXBRL 8-K 27238
2 PRESS RELEASE phio_ex9901.htm EX-99.1 39781
6 GRAPHIC image_001.jpg GRAPHIC 2326
  Complete submission text file 0001683168-24-002050.txt   252185

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE phio-20240402.xsd EX-101.SCH 3021
4 XBRL LABEL FILE phio-20240402_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE phio-20240402_pre.xml EX-101.PRE 22363
18 EXTRACTED XBRL INSTANCE DOCUMENT phio_8k_htm.xml XML 3700
Mailing Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752
Business Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 24812219
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)